SCM
PDLI

Stevens Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Stevens Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-16,305
Closed -$158K – 1453
2014
Q2 		$158K Buy
+16,305
New +$145K ﹤0.01% 959
2014
Q1 		– Sell
-17,523
Closed -$148K – 1517
2013
Q4 		$148K Buy
+17,523
New +$148K ﹤0.01% 943

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stevens Capital Management's PDLI Position: Q3 2014 in Review

Stevens Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 16,305 shares — an estimated $158K sold.

Stevens Capital Management first reported a position in PDLI in Q4 2013 and held it in 2 quarters. The position peaked at $158K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

  • Stevens Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
  • Stevens Capital Management sold 16,305 PDL BioPharma, Inc. shares in Q3 2014, an estimated $158K.
  • Stevens Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 2 quarters.
  • Stevens Capital Management's PDL BioPharma, Inc. position peaked at $158K in Q2 2014.
  • 231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Stevens Capital Management's 13F filing for Q3 2014, filed 7 Nov 2014.